COVID-19 Impact Analysis on United States Induced Pluripotent Stem Cells Market
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the United States induced pluripotent stem cells market. In addition, complete analysis of changes on the United States induced pluripotent stem cells market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The pandemic slackened the economic growth of various countries comprising the U.S., Canada and Mexico. It also resulted in control measures which impacted operations in life science organizations such as production and research. In an article published by Nature Biotechnology, the CEO of flagship Pioneering stated that lab productivity at many of its research-based setup was running at just 30-50% capacity, and even upholding that rate was a challenge. More than 750 trials of cell and gene therapy in almost 30,000 patients were underway as of June 2020, and CGT products account for some 12% of the pharmaceutical industry’s clinical pipeline and at least 16% of its preclinical pipeline. As per the GEP Worldwide, more than 1,200 clinical trials worldwide were disrupted by June 2020. Nearly 61% of clinical trials were disrupted owing to the suspension of patient enrolment. The impact varied owing to changes in COVID-19 case volume throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory diseases, oncology, ID/anti-infectives and cardiovascular diseases were the worst-hit during this time.
Market Overview- United States Induced Pluripotent Stem Cells Market
The factors such as growing investment in basic level research, especially by research organizations and academic institutes in the last few years has led to an increased understanding of the fundamental pathways through which induced pluripotent stem cells market implicated in disease development are either up or down-regulated. This leads to more questions about how biology works, the cause of the diseases and potential diagnoses and treatments. Induced pluripotent stem cells display a particular gene expression signature that is similar to that of embryonic stem cells (ESCs) and exhibit both pluripotency and the capacity of self-renewal.
In the recent years, the complexity of products requested by researchers has grown and this suggests improvement in understanding of the basic pathways and discovery of some new pathways. It is important for manufacturers of research products to keep up with the latest developments to cater to the ever-changing requirements of the life sciences industry.
Stem cell research is attracting wide attention as a promising and fast-growing field in United States, as it is North America. Many countries in the region have defined Regenerative Medicine as a research priority and a focus of investment. This field generates not only opportunities but also regulatory, technical and operative challenges. North America is a fast-growing region conscious of the relevance of stem cell research for the development of Regenerative Medicine, which we think will play a major role in healthcare.
However, factors such as high cost associated with the reprograming of cells, ethical issues and lengthy processes are impeding the induced pluripotent stem cells market growth. Low efficiency, potential tumour risk and incomplete programming are added factors limiting induced pluripotent stem cells market growth.
Stem cell therapy comprises a modern technology whose aim is to replace damaged cells with healthy new ones. Cells are rendered dysfunctional due to any number of factors such as aging, disease, genetic modification, injury. Currently, Stem cell therapies are providing substantial benefit to patients suffering a wide range of diseases such as cancer, non-cancer, neuronal disease, diabetes and injuries such as brain trauma and spinal cord injuries. It is well established and rapidly growing in developed country however in developing country, there are several challenges which is shielding the booming of this therapy. Owing to that, it is expected to eventually remove these challenges to create the fresh environment of modern stem cell therapeutic medicine.
Cumulative Growth Analysis
The report provides in-depth analysis of United States induced pluripotent stem cells market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various induced pluripotent stem cells in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
Market Segmental Overview
The United States induced pluripotent stem cells market comprises of different market segment like Derived Cell Type, Product, Processes, Application and End User.
United States Induced Pluripotent Stem Cells Market by Derived Cell Types
The various derived cell types comprised in the reports are hepatocytes, fibroblasts, keratinocytes and amniotic cells. The hepatocytes segment is likely to dominate the market during the forecast period. Hepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells (iPSCs) hold great promise in toxicological applications as well as in regenerative medicine. Previous efforts on hepatocyte differentiation have mostly relied on the use of growth factors (GFs) to recapitulate developmental signals under in vitro conditions. Recently, the use of small molecules (SMs) has emerged as an attractive tool to induce cell fate transition due to its superiority in terms of both quality and cost. However, HLCs derived using SMs have not been well characterized, especially on the transcriptome level.
United States Induced Pluripotent Stem Cells Market by Product
The certain products comprised in the global induced pluripotent stem cells market are instruments/devices, automated platforms, consumables and kits and services. The instruments/devices segment is likely to dominate the market during the forecast period. The biopharma industry is continuing to adapt more cell-based assays for primary and secondary screening because of higher biological relevance and increased value of information. As part of this evolution, there is a desire to move from immortalized, stable cell lines to primary cells and stem cells. Stem cells offer the advantages of providing better clinical relevance of information compared to cell lines, being available in larger quantities, and having higher assay reproducibility than primary cells. Therefore, there is a great interest in automated stem cell assays to use as screening tools in early drug development, and to evaluate potential toxic effects of new compounds.
United States Induced Pluripotent Stem Cells Market by Processes
The various processes such as manual and automated are comprised in the induced pluripotent stem cells market. The automated manual segment is likely to dominate the market during the forecast period. The various factors such as ability to make any cell or tissue the body might need coupled with government and private sectors are sectors are increasing funding and rising industry that focuses on different research work.
United States Induced Pluripotent Stem Cells Market by Application
The different application of induced pluripotent stems cells comprised in the report are drug development and discovery, toxicity screening and regenerative medicines. The drug development and discovery segment is likely to dominate the market during the forecast period. Stem cells are fast becoming an invaluable tool in the drug discovery process. Stem cells offer the remarkable capacity to generate an unlimited source of disease relevant cell types from which to identify novel molecular targets, perform large-scale phenotypic screens and also identify off-target toxicities.
United States Induced Pluripotent Stem Cells Market by End User
The various end user comprised in the global induced pluripotent stem cells market are hospitals, research laboratories and academic research. The hospitals segment is likely to dominate the market during the forecast period. According to survey conducted by American Hospital Association, there are total, 6,090 hospitals across the United States. In which 5,141 are community hospitals, 208 federal government hospitals, 625 are non-federal psychiatric hospitals and 116 are other hospitals. The National Health Expenditure Accounts (NHEA) are the official estimates of total health care spending in the United States. Dating back of 1960, the NHEA measures annual U.S. expenditures for health care goods and services, public health activities, government administration, the net cost of health insurance, and investment related to health care. The data are presented by type of service, source of funding, and type of sponsor. The vast majority of eye care services in low- and middle-income countries are provided in secondary or tertiary hospitals, which are principally located in urban areas, adds to the inequity in access.
Competitive Landscape Analysis
The competitive landscape analysis of United States induced pluripotent stem cells market is certainly based range of market players operating in the healthcare market with increasing demand for production of induced pluripotent stem cells market. Besides, number of market players offered wide range of products for different application in various geographic locations. The market has major competitive analysis based on new product launches as well as other developments.
The key players studied in market are Fujifilm Holding Corporation, Astellas Pharma Inc., Fate Therapeutics, Inc., Bristol-Myers Squibb Company, ViaCyte, Inc., Celgene Corporation, Aastrom Biosciences, Inc., Acelity Holdings, Inc., StemCells, Inc., Japan Tissue Engineering Co. Ltd. and Organogenesis Inc. among others.
June 2021: Thermo Fisher Scientific Inc. announced that it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company footprints in global market and leading to upsurge company growth in the upcoming years.
June 2020: The LumaCyte collaborated with Catalent who are the global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company stem cell technology product Radiance and its application.